{"_links":{"self":[{}]},"_embedded":{"nice.publications:accreditation-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:accreditation":{"_links":{"nice.publications:logo":[{"href":"/organisation/NICEORG018/AccreditLogo/Normal"}],"self":[{}]},"ETag":null,"Name":"National Institute for Health and Care Excellence (NICE)","Url":"https://www.nice.org.uk"}},"ETag":null},"nice.publications:endorsement-list":{"_links":{"self":[{}]},"ETag":null},"nice.publications:supporting-list":{"_links":{"self":[{}]},"ETag":null},"nice.publications:content-part-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:upload-and-convert-content-part":{"_links":{"self":[{}]},"_embedded":{"nice.publications:html-content":{"_links":{"self":[{"href":"/feeds/product/NG101/content/1/html"}]},"_embedded":{"nice.publications:html-chapter-content-info":[{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/overview"}]},"ETag":null,"Title":"Overview","Reference":"NG101","PartId":1,"ChapterSlug":"overview"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/recommendations"}]},"ETag":null,"Title":"Recommendations","Reference":"NG101","PartId":1,"ChapterSlug":"recommendations"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/recommendations-for-research"}]},"ETag":null,"Title":"Recommendations for research","Reference":"NG101","PartId":1,"ChapterSlug":"recommendations-for-research"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/rationale-and-impact"}]},"ETag":null,"Title":"Rationale and impact","Reference":"NG101","PartId":1,"ChapterSlug":"rationale-and-impact"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/context"}]},"ETag":null,"Title":"Context","Reference":"NG101","PartId":1,"ChapterSlug":"context"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/finding-more-information-and-committee-details"}]},"ETag":null,"Title":"Finding more information and committee details","Reference":"NG101","PartId":1,"ChapterSlug":"finding-more-information-and-committee-details"},{"_links":{"self":[{"href":"/feeds/product/NG101/part/1/chapter/update-information"}]},"ETag":null,"Title":"Update information","Reference":"NG101","PartId":1,"ChapterSlug":"update-information"}]},"ETag":null,"Reference":"NG101","PartId":1},"nice.publications:pdf-file":{"_links":{"self":[{"href":"/feeds/downloads/322d06eb-6368-49c9-8c4b-26b7641836d3"}]},"ETag":null,"Uid":66141532913605,"Id":"322d06eb-6368-49c9-8c4b-26b7641836d3","MimeType":"application/pdf","FileName":"NG101 Guideline 20210518.pdf","Length":326879,"Hash":"F59CF015DF97E330380074E4AC47766842458A3E","Name":"default"},"nice.publications:mobi-file":{"_links":{"self":[{"href":"/feeds/downloads/82bda7ef-024f-4d6a-90fd-a19d434c7774"}]},"ETag":null,"Uid":66141532913602,"Id":"82bda7ef-024f-4d6a-90fd-a19d434c7774","MimeType":"application/x-mobipocket-ebook","FileName":"NG101 Guideline 20210518.mobi","Length":579636,"Hash":"22EEB18B877FB271E849B227DBF5798F409311DD","Name":"default"},"nice.publications:epub-file":{"_links":{"self":[{"href":"/feeds/downloads/0827a4d6-341d-4e81-86ac-a892915af842"}]},"ETag":null,"Uid":66141532913594,"Id":"0827a4d6-341d-4e81-86ac-a892915af842","MimeType":"application/epub+zip","FileName":"NG101 Guideline 20210518.epub","Length":318848,"Hash":"5FB0ED2FDFC60CA1087DA20DCB6827D1A366DB0A","Name":"default"}},"ETag":null,"Title":"Early and locally advanced breast cancer: diagnosis and management","Type":"UploadAndConvertContentPart","Uid":51035133421,"LegacyId":null}},"ETag":null},"nice.publications:related-resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:related-resource":[{"_links":{"self":[{"href":"/feeds/resource/29441"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29441"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"Evidence reviews – July 2018","ResourceType":"EvidenceReview","Status":"Published","Language":"English","Uid":3784465},{"_links":{"self":[{"href":"/feeds/resource/29442"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29442"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"Full guideline – February 2009","ResourceType":"FullGuidance","Status":"Published","Language":"English","Uid":3784466},{"_links":{"self":[{"href":"/feeds/resource/29443"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29443"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"Evidence review – February 2009","ResourceType":"EvidenceReview","Status":"Published","Language":"English","Uid":3784467},{"_links":{"self":[{"href":"/feeds/resource/29445"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29445"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"AuditAndServiceImprovement"}},"ETag":null}},"ETag":null,"Title":"Baseline assessment tool","ResourceType":"AuditAndServiceImprovement","Status":"Published","Language":"English","Uid":3784469},{"_links":{"self":[{"href":"/feeds/resource/29447"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29447"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"Methods","ResourceType":"OtherSupportingEvidence","Status":"Published","Language":"English","Uid":3784471},{"_links":{"self":[{"href":"/feeds/resource/29448"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29448"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"InformationForThePublic"}},"ETag":null}},"ETag":null,"Title":"Early and locally advanced breast cancer: diagnosis and management","ResourceType":"InformationForThePublic","Status":"Published","Language":"English","Uid":3784472},{"_links":{"self":[{"href":"/feeds/resource/29570"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/29570"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"ResourceImpact"}},"ETag":null}},"ETag":null,"Title":"Resource impact statement","ResourceType":"ResourceImpact","Status":"Published","Language":"English","Uid":3785868},{"_links":{"self":[{"href":"/feeds/resource/32745"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/32745"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"InformationForThePublic"}},"ETag":null}},"ETag":null,"Title":"Gwybodaeth i'r cyhoedd ","ResourceType":"InformationForThePublic","Status":"Published","Language":"Welsh","Uid":5141381},{"_links":{"self":[{"href":"/feeds/resource/39169"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/39169"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"2020 exceptional surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)","ResourceType":"SurveillanceReport","Status":"Published","Language":"English","Uid":5460273},{"_links":{"self":[{"href":"/feeds/resource/53126"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/53126"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"2022 exceptional surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)","ResourceType":"SurveillanceReport","Status":"Published","Language":"English","Uid":8539422},{"_links":{"self":[{"href":"/feeds/resource/54693"},{}],"nice.publications:related-resource-uri":[{"href":"/feeds/resource/54693"}]},"_embedded":{"nice.publications:resource-group-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:resource-group":{"_links":{"self":[{}]},"ETag":null,"Name":"Evidence"}},"ETag":null}},"ETag":null,"Title":"2022 exceptional surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)","ResourceType":"SurveillanceReport","Status":"Published","Language":"English","Uid":8592807}]},"ETag":null},"nice.publications:related-product-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:related-product":[{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/TA107"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"Replaces"}},"ETag":null}},"ETag":null,"Title":"Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer","ShortTitle":null,"Id":"TA107"},{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/TA108"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"Replaces"}},"ETag":null}},"ETag":null,"Title":"Paclitaxel for the adjuvant treatment of early node-positive breast cancer","ShortTitle":null,"Id":"TA108"},{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/TA109"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"Replaces"}},"ETag":null}},"ETag":null,"Title":"Docetaxel for the adjuvant treatment of early node-positive breast cancer","ShortTitle":null,"Id":"TA109"},{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/TA112"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"Replaces"}},"ETag":null}},"ETag":null,"Title":"Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer","ShortTitle":null,"Id":"TA112"},{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/QS12"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"IsTheBasisOf"}},"ETag":null}},"ETag":null,"Title":"Breast cancer","ShortTitle":null,"Id":"QS12"},{"_links":{"nice.publications:related-product-uri":[{"href":"/feeds/product/ES15"}],"self":[{}]},"_embedded":{"nice.publications:product-relationship-list":{"_links":{"self":[{}]},"_embedded":{"nice.publications:product-relationship":{"_links":{"self":[{}]},"ETag":null,"Relation":"Replaces"}},"ETag":null}},"ETag":null,"Title":"Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates","ShortTitle":null,"Id":"ES15"}]},"ETag":null}},"ETag":"01000000-0000-0001-0000-00000000EF8B","Id":"NG101","LastModified":"2022-07-13T15:24:34.1156525Z","ProductType":"NG","Title":"Early and locally advanced breast cancer: diagnosis and management","ShortTitle":null,"InDevReference":"GID-NG10016","MetaDescription":"This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences","Summary":"<p class=\"lead\">This guideline covers diagnosing and managing early and locally advanced breast cancer. It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.</p>\n<p><em class=\"icon-nice-warning\">&nbsp;</em>A <a href=\"https://www.nice.org.uk/guidance/ng161/resources/\">table of NHS England interim treatment regimens</a> gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with early and locally advanced breast cancer. See the <a href=\"https://www.nice.org.uk/guidance/ng161\">COVID-19 rapid guideline: delivery of systemic anticancer treatments</a> for more details.</p>\n<p>We have also produced <a href=\"https://www.nice.org.uk/guidance/cg81\">guidelines on advanced breast cancer</a>,&nbsp;<a href=\"https://www.nice.org.uk/guidance/cg164\">familial breast cancer</a>&nbsp;and&nbsp;<a href=\"https://www.nice.org.uk/guidance/ng12\">suspected cancer: recognition and referral</a>.</p>\n<h2>Recommendations</h2>\n<p>This guideline includes new and updated recommendations on:</p>\n<ul>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#surgery-to-the-breast\">surgery to the breast and axilla</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#breast-reconstruction\">breast reconstruction</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#diagnostic-assessment-and-adjuvant-therapy-planning\">diagnostic assessment and adjuvant therapy planning</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#endocrine-therapy\">endocrine therapy</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#adjuvant-chemotherapy-for-invasive-breast-cancer\">adjuvant chemotherapy for invasive breast cancer</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#bisphosphonate-therapy\">bisphosphonate therapy</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#radiotherapy\">radiotherapy</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#primary-systemic-therapy\">primary systemic therapy</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#lymphoedema\">lymphoedema</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#lifestyle\">lifestyle</a></li>\n</ul>\n<p>These supplement the existing recommendations on:</p>\n<ul>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#referral-diagnosis-and-preoperative-assessment\">referral, diagnosis and preoperative assessment</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#providing-information-and-psychological-support\">providing information and psychological support</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#complications-of-local-treatment-and-menopausal-symptoms\">complications of local treatment and menopausal symptoms</a></li>\n<li><a href=\"https://www.nice.org.uk/guidance/ng101/chapter/Recommendations#followup\">follow-up</a></li>\n</ul>\n<h2>Who is it for?</h2>\n<ul>\n<li>Healthcare professionals</li>\n<li>Commissioners and providers of breast cancer services</li>\n<li>People with early and locally advanced breast cancer, their families and carers</li>\n</ul>\n<h2>Is this guideline up to date?</h2>\n<p>July 2022: We have checked this guideline and plan to update the recommendations on radiotherapy. The update will focus on dose fractionation. For more information, see the <a href=\"https://www.nice.org.uk/guidance/ng101/resources/2022-exceptional-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-11136277837/chapter/Surveillance-decision?tab=evidence\">July 2022 surveillance decision</a>.</p>\n<p>May 2022: We checked this guideline and are updating the recommendations on strategies for reducing arm and shoulder mobility problems after breast cancer surgery. For more information, see the <a href=\"https://www.nice.org.uk/guidance/ng101/resources/2022-exceptional-surveillance-of-early-and-locally-advanced-breast-cancer-diagnosis-and-management-nice-guideline-ng101-11067090877/chapter/Surveillance-decision?tab=evidence\">May 2022 surveillance decision</a>. See the&nbsp;<a href=\"https://www.nice.org.uk/guidance/indevelopment/gid-ng10354\">guideline in development page</a>&nbsp;for progress on the update.</p>\n<h2>Guideline development process</h2>\n<p><a href=\"https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/how-we-develop-nice-guidelines\">How we develop NICE guidelines</a></p>\n<p>This guideline updates and replaces NICE guideline CG80 (February 2009), NICE technology appraisal guidance 107, 108, 109 and 112 (published 2006) and NICE evidence summary ES15.</p>","ProductStatus":"Published","VersionNumber":25,"PublishedDate":"2018-07-18T00:00:00","LastMajorModificationDate":"2018-07-18T00:00:00","MajorChangeDate":null,"NextReviewDate":null,"CollectionTypesList":[],"AuthorList":["National Institute for Health and Care Excellence (NICE)"],"PublisherList":["National Institute for Health and Care Excellence (NICE)"],"AudienceList":[],"EstimatedSavings":"","EstimatedSavingsDescription":"","EstimatedSavingsImpact":null,"DevelopedAs":"CG","RelevantTo":[],"TerminatedAppraisal":null,"AreasOfInterestList":[],"IndicatorSubTypeList":[],"IndicatorOldCode":null,"IndicatorOldUrl":null,"IPSV":"Health, well-being and care","ChapterHeadings":[{"Title":"Overview","Url":"/NG101"},{"Title":"Recommendations","Url":"/NG101/chapter/Recommendations"},{"Title":"Recommendations for research","Url":"/NG101/chapter/Recommendations-for-research"},{"Title":"Rationale and impact","Url":"/NG101/chapter/Rationale-and-impact"},{"Title":"Context","Url":"/NG101/chapter/Context"},{"Title":"Finding more information and committee details","Url":"/NG101/chapter/Finding-more-information-and-committee-details"},{"Title":"Update information","Url":"/NG101/chapter/Update-information"}],"ProductTypeName":"NICE guideline","ProductTypeNamePlural":"NICE guidelines"}
